Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US
DGAP-News: Heidelberg Pharma AG
/ Key word(s): Miscellaneous
Heidelberg Pharma provides update on Phase I/IIa clinical trial with ATAC candidate HDP-101 in the US
- Compatibility tests for closed infusion system with HDP-101 successfully completed
Ladenburg, Germany, 7 September 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that preparations for the initiation of the Phase I/IIa clinical trial with HDP-101 have progressed and the initiation of the first study site, the MD Anderson Cancer Center, Houston, TX, US, is planned shortly.
The clinical trial will evaluate the ATAC candidate HDP-101 in patients with multiple myeloma, a type of bone marrow cancer with a high unmet medical need. As HDP-101 is an antibody drug conjugate loaded with a toxin, Amanitin, the use of a special closed system transfer device (CSTD) for infusion of the study medication is required in the US to protect hospital staff from accidental contact with the agent. The mandatory compatibility tests of HDP-101 with the device used by MD Anderson have been carried out in recent weeks and have been successfully completed. The CSTD can thus be used for the infusion of HDP-101 in the clinical trial. The documentation of the study medication is being updated accordingly and will then be sent to the US study site.
The contract with MD Anderson, the first of several planned study centers in the US, has been signed, and the physicians and medical staff have been trained to conduct the study. An official initiation of the study center is planned for the second half of September.
"We are pleased that we were able to advance our preparations for the start of the study in the US during the summer and that we are now close to initiating the first study site. Not only have our employees been working towards this moment for a long time, but patients with multiple myeloma and limited therapy options are also hoping for new treatment approaches," commented Prof. Dr. Andreas Pahl, Chief Scientific Officer of Heidelberg Pharma AG.
About the Phase I/IIa study with HDP-101
The two parts of the open-label, multicenter Phase I/IIa study will enroll up to 36 and 30 patients, respectively. Patients in the Phase IIa part will be stratified based on their 17p deletion status. Preclinical data show that Amanitin has the potential to be especially effective against tumors that have changed due to so-called 17p deletion mutations to bypass a special mechanism of cell protection. Patients with such a deletion usually show a poorer response to standard therapies and have a significantly worse prognosis. The Phase IIa part of the trial is intended to evaluate not only the efficacy of HDP-101 in multiple myeloma patients, but also the clinical relevance of the 17p deletion.
About Heidelberg Pharma
Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com.
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
07.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Company:||Heidelberg Pharma AG|
|Phone:||+49 (0)89 41 31 38 - 0|
|Fax:||+49 (0)89 41 31 38 - 99|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1231608|
|End of News||DGAP News Service|